Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Chimeric antigen receptor (CAR)-based cell therapy, originally for hematological malignancies, is a novel approach for autoimmune diseases.
• CAR T cell therapy has demonstrated long-term, drug-free remission in various autoimmune conditions.
• The field is rapidly evolving with CAR natural killer (NK) cells, CAR regulatory T (Treg) cells, and CAR mesenchymal stem cells (MSCs) showing early promise.

Purpose of the Study:

• To review the effectiveness and applicability of CAR-based immunotherapy in managing autoimmune diseases.
• To explore the limitations and future directions of CAR cell therapies for autoimmune conditions.
• To highlight the transition of CAR cell therapies from preclinical research to clinical application.

Main Methods:

• Review of current literature on CAR cell therapy in autoimmune diseases.
• Analysis of clinical trial data for CAR T, CAR NK, CAR Treg, and CAR MSC therapies.
• Discussion of the mechanisms of action and therapeutic potential.

Main Results:

• CAR T cell therapy has achieved sustained remission in several autoimmune diseases without requiring ongoing medication.
• Early-stage clinical trials indicate promising efficacy and safety profiles for CAR NK cell therapy.
• Emerging CAR Treg and CAR MSC therapies have also yielded initial positive outcomes.

Conclusions:

• CAR-based cell therapies represent a significant advancement in treating autoimmune diseases, offering potential for durable, drug-free remission.
• Continued research and development are crucial for optimizing CAR cell products for enhanced safety, efficacy, and convenience.
• The expanding applications of CAR cell technologies herald a new era in autoimmune disease management.